Drug Trial Radar · NCT00389909
Dosing Chart for Calculating the First Dose of Doxapram in Premature Infants
Last checked: Nov 20, 2026Latest source record: Feb 27, 2017 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
85
Actual
Start
Nov 2006
Primary completion
Nov 2010
Study completion Nov 2010
Sponsor
- Lead sponsor
- Jean Michel HascoetAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Oct 19, 2006
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 1 week, up to 3 months
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Doxapram is used to stimulate respiration. For a given dose, the fluctuations in concentrations observed in infants' blood may be wide, leading to a risk of lack of efficacy or of toxic effects. Two factors are linked to these fluctuations: age and gender. The aim of this study is to compare a dosage regimen based only on patient's weight, to another one using a dosing chart taking into account weight, age and gender.
Conditions
- Premature Infants
- Apnea
Interventions
DoxapramDrug
Dosing comparison between fixed scheduled and sex related dosage. Dosing related to weight only versus chart taking into account weight, age and gender.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Plasma level of Doxapram and its active metabolite (ketodoxapram) at 48 hours after the onset of treatment.Time frame: 48 Hours
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Maternite Regionale Universitaire
Nancy, France
Hopital des Enfants
Toulouse, France
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.